

#### Q3 2016 FINANCIAL RESULTS November 3, 2016

# FORWARD-LOOKING AND CAUTIONARY STATEMENTS



This Presentation on behalf of KP Tissue Inc. (the "Corporation" or "KPT") does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever.

The information contained in this Presentation does not purport to be all-inclusive. This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of securities law.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of the directors, officers or employees of any such entities as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each person receiving this Presentation should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.


Certain statements in this presentation about the Corporation and Kruger Products L.P. ("KPLP") as it relates to their current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking information is based on certain key expectations and assumptions made by the Corporation or KPLP, including the continued growth of the U.S. private label market and the continued growth in sales of TAD products in the U.S., orders for the TAD machine's products, the amount and timing of distributions made by KPLP, and Kruger Inc.'s ("Kruger") cash requirements. The financial outlook that KPLP Management provides concerning the potential incremental Adjusted EBITDA generated by TAD products may be considered forward-looking information and is based on additional key expectations and assumptions, including but not limited to (i) limited incremental overhead relating to the operation of the TAD machine and distribution and sale of products, (ii) the TAD machine operating at near full capacity and products being sold at prices consistent with current market prices, adjusted for inflation, (iii) a cost of pulp and energy and a selling price of finished products based on recent prices, adjusted for inflation and (iv) a foreign exchange rate between the Canadian and U.S. dollars approximating current levels. The financial outlook provided in respect of Adjusted EBITDA for Q4 2016 may be considered forward-looking information and is based on additional key expectations and assumptions, including but not limited to (i) sales volumes consistent with management's expectations, (ii) a cost of pulp and energy based on recent prices, and (iii) a foreign exchange rate between the Canadian and U.S. dollars approximating current levels. The purpose of the outlook is to provide the reader with an indication of management's expectations, at the date of this conference call, regarding KPLP's future financial performance. Readers are cautioned that this information may not be appropriate for other purposes. Although the Corporation and KPLP believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information since no assurance can be given that such expectations and assumptions will prove to be correct.

Unless otherwise stated, references in this presentation to market shares or KPT's market leadership are based on Nielsen dollar market share data and management estimates.

The following presentation is to review Kruger Products L.P. Q3 2016 financial results

#### CORPORATE STRUCTURE

83.9%





Kruger Products L.P. is the operating company. KP Tissue Inc. is the publicly traded entity.

\* As of August 10, 2016 (16.2% as of June 26, 2016)

## Q3 2016 HIGHLIGHTS


- Q3 2016 revenue of \$312.8 million, up 6.5% over Q3 2015, driven primarily by higher sales volume and a selling price increase in Canada. Revenue was up in all geographic regions
- Adjusted EBITDA<sup>1</sup> of \$45.7 million compared to \$34.8 million last year primarily due to higher sales volume, improved pricing, strong manufacturing performance and operating efficiencies, a more favourable product mix and cost reduction initiatives
- Adjusted EBITDA from TAD products<sup>2</sup> of \$12.7 million, up from \$11.2 million in Q3 2015
- Net Income of \$21.6 million in the quarter compared to a loss of \$5.9 million in Q3 2015


<sup>1</sup> Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure <sup>2</sup> Represents Adjusted EBITDA attributable to the sale of KTG's TAD products

	Bathroom Tissue	Facial Tissue	Paper Towel
<b>Kruger</b> Products	#1 <b>36.8%</b>	#1 <b>31.5%</b>	#2 23.8%
IRVING	21.1%	20.3%	9.8%
P&G	10.2%	1.0%	32.3%
B Kimberly-Clark	4.4%	18.2%	2.6%

Source: Nielsen; dollar market share for the 52-week period ended September 17, 2016.

#### **BRAND LEADERSHIP POSITION**





Ended September 17, 2016


Ended September 17, 2016

2008 2009 2010 2011 2012 2013 2014 2015 2016

Source: Nielsen Canadian dollar market share for 52-week period data.

### PULP INPUT PRICES

- Q3 pulp prices (NBSK) rose sequentially compared to Q2 2016 in both USD and CAD and also year-overyear in CAD. Eucalyptus prices (BEK) were lower however.
- Based on industry information, management expects pulp prices in USD to remain relatively stable in the near term. The continuing weak and volatile CAD will further create fluctuations in pulp input costs during 2016.



7

# QUARTERLY FINANCIAL SUMMARY



				% Chan	ge
(C\$ millions, unless otherwise noted)	Q3 2016	Q2 2016	Q3 2015	Y/Y	Q/Q
Revenue	312.8	295.8	293.6	6.5%	5.7%
Cost of Sales	256.8	249.9	248.0		
Gross Profit	56.0	45.9	45.6	22.8%	22.0%
Gross Margin	17.9%	15.5%	15.5%		
Adjusted EBITDA	45.7	35.9	34.8	31.3%	27.3%
Adjusted EBITDA Margin	14.6%	12.1%	11.9%		
Operating Income (EBIT)	33.7	23.5	24.3		
EBIT Margin	10.8%	7.9%	8.3%		
Net Income (Loss)	21.6	12.0	(5.9)		
Net Income Margin	6.9%	4.1%	-2.0%		

# QUARTERLY SEGMENTED RESULTS



#### **QUARTERLY SEGMENTED RESULTS**

				% Chan	ge
(C\$ millions, unless otherwise noted)	Q3 2016	Q2 2016	Q3 2015	Y/Y	Q/Q
Segmented Revenue					
•	240.0	222.4	220.2	0.10/	7 40/
Consumer	248.8	232.4	230.2	8.1%	7.1%
AFH	59.4	59.1	59.5	(0.2)%	0.5%
Other	4.6	4.3	3.9		
Total segment revenue	312.8	295.8	293.6	6.5%	5.7%
Segment Adjusted EBITDA					
Consumer	43.9	34.1	32.3	35.8%	28.7%
AFH	1.5	1.4	1.8	(14.9)%	7.1%
Other	0.3	0.4	0.7		
Total segment Adjusted EBITDA	45.7	35.9	34.8	31.2%	27.3%
Segment Adjusted EBITDA Margin					
Consumer	17.6%	14.7%	14.0%		
AFH	2.5%	2.4%	3.0%		
Other					
Total segment Adjusted EBITDA Margi	14.6%	12.1%	11.9%		

# Q3 2016 REVENUE COMPARED TO Q3 2015

- Q3 2016 revenue increased by \$19.2 million or 6.5% over Q3 2015 primarily due to the following factors:
  - Consumer segment revenue increased \$18.6 million or 8.1% driven by sales volume growth in all geographic regions, as well as a selling price increase in Canada. F/X impact on revenue was not significant
  - AFH segment revenue was flat

From a geographic perspective:

- Revenue in the U.S. increased by \$7.3 million or 7.2%, due primarily to higher sales volume in the Consumer segment
- Revenue increased in Canada by \$7.8 million, or 4.3%, and in Mexico increased \$4.1 million or 48.3%

# Q3 2016 ADJUSTED EBITDA COMPARED TO Q3 2015



- Q3 2016 Adjusted EBITDA increased by \$10.9 million or 31.3% compared to Q3 2015 due to the following factors:
  - Higher sales volume in the Consumer segment
  - Improved pricing in Canadian Consumer segment
  - More favourable product mix
  - Cost reduction initiatives
  - Strong manufacturing performance and operating efficiencies
  - Benefit of previously initiated capital projects
- Gross margin increased (17.9% in Q3 2016 versus 15.5% in Q3 2015) primarily due to the above mentioned factors

# Q3 2016 REVENUE COMPARED TO Q2 2016

- Q3 2016 revenue increased by \$17.0 million or 5.7% over Q2 2016, primarily due to:
  - Consumer segment revenue increased by \$16.4 million or 7.1% due to higher sales volume and improved pricing in the Canadian Consumer segment
  - AFH segment revenue was flat

From a geographic perspective:

- Revenue increased in Canada by \$11.0 million or 6.1%
- Revenue increased in the U.S. by \$6.4 million or 6.2%

# Q3 2016 ADJUSTED EBITDA COMPARED TO Q2 2016



- Q3 2016 Adjusted EBITDA increased by \$9.8 million over Q2 2016 due to the combination of the following factors:
  - Higher sales volumes in Canada and the U.S.
  - Improved pricing in the Canadian Consumer segment
  - More favourable product mix
  - Cost reduction initiatives
  - Benefit of previously initiated capital projects
- Gross margin increased (17.9% in Q3 2016 versus 15.5% in Q2 2016) primarily due to the above mentioned factors



	Q3 2016	Q2 2016
Cash & cash equivalents	19.5	10.1
Current portion of long-term debt	9.0	9.1
Long-term debt	415.7	408.4
Net Debt	405.1	407.5
LTM EBITDA	139.9	129.0
Net Debt/LTM EBITDA	2.9	3.2




- Q3 2016 CAPEX of \$20.0 million, up from \$17.3 million in Q3 2015
- Year-to-date CAPEX of \$58.7 million, up from \$35.1 million last year
- 2016 focus on high return CAPEX projects total estimated at approximately \$80-\$90 million (from prior range of \$80-\$95 million)

CAPEX COMPONENTS	Fiscal 2016 %
Capacity/Growth	48%
Cost reductions	27%
Maintenance	25%
Total	100%

Cost reduction and Capacity/Growth projects generally have 3 to 4 year paybacks

## TAD PRODUCT





- Q3 2016 Adjusted EBITDA from TAD products of \$12.7 million, up from \$11.2 million in Q3 2015
- YTD 2016 Adjusted EBITDA from TAD products of \$35.2 million, up from \$32.1 million in YTD 2015
- Adjusted EBITDA from TAD products for Q4 2016 expected to be higher than Q4 2015, primarily due to sales ramp-up from new customers
- Our outlook for Fiscal 2017 Adjusted EBITDA remains at \$60 million for TAD products

### CONCLUSION

- Very solid quarter for the Canadian Consumer business (price/volume)
- Maintain market share leadership in Canadian consumer segment in the context of a competitive and price sensitive environment
- Cost reduction program and previously initiated capital projects are delivering according to plan
- Leverage TAD product manufacturing capacity to take advantage of growth opportunities in the U.S. premium private label market
- AFH segment complete new production line projects to improve manufacturing costs with anticipated benefits starting in Fiscal 2017

### CONCLUSION

- New paper machine in Crabtree primarily dedicated to AFH with CAPEX of \$55 million. Construction started in August. Expected benefits starting in Fiscal 2018
- Above normal CAPEX in Fiscal 2016 dedicated to improve profitability and manufacturing efficiencies, both in the Consumer and AFH segments – estimated at \$80-\$90 million. Benefits on Adjusted EBITDA will start in Fiscal 2017
- Adjusted EBITDA for Q4 2016 is expected to increase over last year and decline when compared with the third quarter of 2016, reflecting seasonality



#### FOR MORE INFORMATION:

WWW.KPTISSUEINC.COM WWW.KRUGERPRODUCTS.CA